Duration of Progynova (Estradiol) for HRT-FET Protocol
Continue Progynova for approximately 5-7 more days until endometrial thickness reaches ≥8mm, then initiate progesterone supplementation. The current endometrial thickness of 7.2mm on day 9 is approaching but has not yet reached the optimal threshold for progesterone initiation in a hormone replacement therapy frozen embryo transfer (HRT-FET) cycle.
Endometrial Preparation Timeline
Current Status Assessment
- Day 9 with 7.2mm endometrium requires continued estrogen priming before progesterone initiation 1
- The target endometrial thickness is ≥8mm, with optimal outcomes seen at thicknesses >7mm 1
- Clinical pregnancy rates increase progressively with endometrial thickening in HRT-FET cycles 1
Estrogen Continuation Protocol
- Continue 12mg Progynova daily until endometrial thickness reaches 8-10mm 1
- Typical duration of estrogen priming in HRT-FET protocols ranges from 12-18 days total before progesterone initiation 2, 3
- Monitor endometrial thickness every 2-3 days after day 10 to determine optimal timing for progesterone start 1
Progesterone Initiation Timing
- Begin progesterone supplementation once endometrial thickness is ≥8mm, typically occurring around days 14-16 of the cycle 2, 3
- The timing of progesterone start is critical for embryo-endometrial synchronization in FET cycles 3
- For a day 5 blastocyst transfer, progesterone should be administered for 5 days before transfer; for a day 3 embryo, 3 days of progesterone exposure is needed 2, 3
Progesterone Supplementation Regimen (Once Initiated)
Recommended Progesterone Protocol
- Vaginal micronized progesterone 200mg three times daily (600mg total) is the preferred first-line regimen for HRT-FET cycles due to higher intrauterine concentrations via first uterine pass effect 2, 4
- Alternative: Intramuscular progesterone may provide superior outcomes in some studies, with one RCT showing improved clinical pregnancy rates (RR 1.46,95% CI 1.21-1.76) and live birth rates (RR 1.62,95% CI 1.28-2.05) compared to vaginal administration 4
- Target serum progesterone concentration on day 16 of the cycle (approximately 5 days after progesterone initiation) should be >50 nmol/L (>15.8 ng/mL) for optimal outcomes 5
Monitoring and Adjustment
- Measure serum progesterone concentration 5 days after initiating progesterone to ensure adequate levels 5
- Live birth rates are significantly higher with day 16 progesterone >50 nmol/L (26.4% vs 11.3% for <50 nmol/L; adjusted OR 3.14,95% CI 2.21-4.48) 5
- Pregnancy loss rates are lower with adequate progesterone levels (14.3% vs 32.6% for ≤50 nmol/L; adjusted OR 0.26,95% CI 0.12-0.58) 5
Critical Pitfalls to Avoid
Premature Progesterone Initiation
- Do not start progesterone with endometrial thickness <7mm, as this is associated with significantly worse outcomes 1
- Starting progesterone too early disrupts the window of implantation and reduces embryo-endometrial synchronization 2, 3
Inadequate Progesterone Dosing
- A significant proportion of patients do not reach adequate progesterone concentrations regardless of administration route, necessitating individualized monitoring 2
- There is positive correlation between live births and both the number of progesterone doses per day (r = 0.119, P = 0.026) and day 16 progesterone concentrations (r = 0.128, P = 0.011) 5
Thin Endometrium Management
- If endometrial thickness remains <7mm after 14-16 days of Progynova, consider adding vaginal Femoston (estradiol/dydrogesterone combination) to improve endometrial receptivity 1
- Patients with thin endometrium who received combined Progynova plus Femoston showed improved clinical pregnancy rates compared to historical controls with Progynova alone 1
Estrogen Continuation During Progesterone Phase
- Continue Progynova at the same dose (12mg daily) throughout progesterone supplementation and after embryo transfer 2, 3
- Estrogen support should be maintained until at least 10-12 weeks of gestation if pregnancy is achieved 2
- There is no consensus on optimal estradiol levels, but monitoring is less critical than ensuring adequate progesterone concentrations 2, 1